$ERNA
Eterna Therapeutics Inc.

2023 Q2 Form 10-Q Financial Statement

#000114036123024180 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $50.00K
YoY Change
Gross Profit $0.00 -$50.00K
YoY Change
Gross Profit Margin
Selling, General & Admin $2.510M $3.590M $4.514M
YoY Change -53.8% -20.47% 169.81%
% of Gross Profit
Research & Development $1.579M $1.674M $1.782M
YoY Change -6.29% -6.06% 16.24%
% of Gross Profit
Depreciation & Amortization $20.00K $21.00K $36.00K
YoY Change -70.59% -41.67% 42.37%
% of Gross Profit
Operating Expenses $4.549M $5.316M $6.296M
YoY Change -67.23% -15.57% -29.42%
Operating Profit -$4.549M -$5.316M -$6.296M
YoY Change -67.23% -15.57% -29.42%
Interest Expense $20.00K -$50.00K -$615.0K
YoY Change -106.76% -91.87%
% of Operating Profit
Other Income/Expense, Net $45.00K -$95.00K -$3.079M
YoY Change -99.57% -96.91% -67.93%
Pretax Income -$4.504M -$5.411M -$9.375M
YoY Change 32.55% -42.28% -49.38%
Income Tax $4.000K $5.000K $0.00
% Of Pretax Income
Net Earnings -$4.508M -$5.400M -$9.400M
YoY Change 32.59% -42.55% -49.25%
Net Earnings / Revenue
Basic Earnings Per Share -$0.85 -$1.06 -$0.17
Diluted Earnings Per Share -$0.85 -$1.06 -$0.17
COMMON SHARES
Basic Shares Outstanding 5.270M 5.127M 53.63K
Diluted Shares Outstanding 5.303M 5.127M 53.63K

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.840M $5.400M $23.50M
YoY Change -90.52% -77.02% 179.43%
Cash & Equivalents $1.837M $5.397M $23.50M
Short-Term Investments
Other Short-Term Assets $1.070M $470.0K $800.0K
YoY Change -41.34% -41.25% 219.69%
Inventory
Prepaid Expenses
Receivables $980.0K $650.0K
Other Receivables $984.0K $647.0K
Total Short-Term Assets $3.891M $6.515M $25.14M
YoY Change -82.25% -74.08% 188.46%
LONG-TERM ASSETS
Property, Plant & Equipment $193.0K $215.0K $1.786M
YoY Change -54.48% -87.96% 213.92%
Goodwill $2.000M $2.000M $2.000M
YoY Change 0.0% 0.0% -2.14%
Intangibles
YoY Change
Long-Term Investments $0.00 $8.000K $421.0K
YoY Change -100.0% -98.1% -13.82%
Other Assets $1.374M $1.242M
YoY Change
Total Long-Term Assets $43.06M $8.593M $10.24M
YoY Change 765.24% -16.09% -14.55%
TOTAL ASSETS
Total Short-Term Assets $3.891M $6.515M $25.14M
Total Long-Term Assets $43.06M $8.593M $10.24M
Total Assets $46.95M $15.11M $35.38M
YoY Change 74.54% -57.29% 70.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.675M $1.461M $1.106M
YoY Change 80.99% 32.1% -38.96%
Accrued Expenses $2.109M $2.012M $2.384M
YoY Change -44.81% -15.6% 105.46%
Deferred Revenue
YoY Change
Short-Term Debt $1.750M $1.750M $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.165M $5.406M $3.684M
YoY Change 0.66% 46.74% -5.59%
LONG-TERM LIABILITIES
Long-Term Debt $330.0K $770.0K $0.00
YoY Change -100.0%
Other Long-Term Liabilities $35.59M $87.00K $14.38M
YoY Change 74045.83% -99.4% 62800.76%
Total Long-Term Liabilities $35.92M $87.00K $14.38M
YoY Change 74733.33% -99.4% 62800.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.165M $5.406M $3.684M
Total Long-Term Liabilities $35.92M $87.00K $14.38M
Total Liabilities $43.09M $7.728M $18.07M
YoY Change 255.42% -57.22% -28.08%
SHAREHOLDERS EQUITY
Retained Earnings -$175.2M -$170.7M -$150.1M
YoY Change 14.14% 13.72% 172.5%
Common Stock $27.00K $26.00K
YoY Change -90.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.866M $7.380M $17.31M
YoY Change
Total Liabilities & Shareholders Equity $46.95M $15.11M $35.38M
YoY Change 74.54% -57.29% 70.91%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$4.508M -$5.400M -$9.400M
YoY Change 32.59% -42.55% -49.25%
Depreciation, Depletion And Amortization $20.00K $21.00K $36.00K
YoY Change -70.59% -41.67% 42.37%
Cash From Operating Activities -$3.870M -$6.000M -$5.400M
YoY Change -3.08% 11.11% 57.44%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$46.00K
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00 -$46.00K
YoY Change -100.0% -100.0% -117.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 310.0K 0.000 11.99M
YoY Change -2484.62% -100.0% 20.62%
NET CHANGE
Cash From Operating Activities -3.870M -6.000M -5.400M
Cash From Investing Activities 0.000 0.000 -46.00K
Cash From Financing Activities 310.0K 0.000 11.99M
Net Change In Cash -3.560M -6.000M -5.400M
YoY Change -13.02% 11.11% -179.65%
FREE CASH FLOW
Cash From Operating Activities -$3.870M -$6.000M -$5.400M
Capital Expenditures $0.00 $0.00 -$46.00K
Free Cash Flow -$3.870M -$6.000M -$5.354M
YoY Change 1.68% 12.07% 56.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000748592
CY2023Q1 erna License Agreement Automatic Renewal Term
LicenseAgreementAutomaticRenewalTerm
P2Y6M
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
87000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
94000
CY2023Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1750000
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1750000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
8000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
363000
CY2023Q1 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
768000
CY2022Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
1206000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3079000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5411000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5127000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5127000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5127000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5127000
CY2023Q1 erna License Costs
LicenseCosts
50000
CY2022Q1 erna License Costs
LicenseCosts
0
CY2023Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1674000
CY2022Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1782000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3592000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4514000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
5316000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
6296000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5316000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6296000
CY2023Q1 erna Warrant Liabilities Expense
WarrantLiabilitiesExpense
45000
CY2022Q1 erna Warrant Liabilities Expense
WarrantLiabilitiesExpense
1322000
CY2023Q1 erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
51000
CY2022Q1 erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
615000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1142000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-95000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9375000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5416000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9375000
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.06
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.06
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.5
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.5
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5127000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5127000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2681000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2681000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12107000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
689000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5416000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7380000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25503000
CY2022Q1 erna Stock Issued During Period Value Of Common Stock And Prefunded Warrants In Connection With Private Offering Net Of Offering Costs
StockIssuedDuringPeriodValueOfCommonStockAndPrefundedWarrantsInConnectionWithPrivateOfferingNetOfOfferingCosts
0
CY2022Q1 erna Stock Issued During Period Value Forfeiture Of Unvested Restricted Stock
StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
0
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1183000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9375000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
17311000
CY2023Q1 erna Warrant Liabilities Expense
WarrantLiabilitiesExpense
45000
CY2022Q1 erna Warrant Liabilities Expense
WarrantLiabilitiesExpense
1322000
CY2023Q1 us-gaap Sublease Income
SubleaseIncome
21000
CY2023Q1 erna Period Of Purchase Agreement
PeriodOfPurchaseAgreement
P2Y
CY2023Q1 erna Proceeds From Option And License Agreement
ProceedsFromOptionAndLicenseAgreement
250000
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
1
CY2023Q1 erna Deferred Revenue Related To Upfront And Nonrefundable Option Fee
DeferredRevenueRelatedToUpfrontAndNonrefundableOptionFee
250000
CY2023Q1 erna Option Fee Obligation Payment Percentage
OptionFeeObligationPaymentPercentage
0.20
CY2023Q1 erna License Costs
LicenseCosts
50000
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
331000
CY2023Q1 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
45000
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
376000
CY2022Q1 erna Operating Lease Area
OperatingLeaseArea
5200
CY2022Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P62M
CY2022Q1 erna Initial Measurement Of Operating Lease Rou Assets
InitialMeasurementOfOperatingLeaseROUAssets
1700000
CY2022Q1 erna Initial Measurement Of Operating Lease Liabilities
InitialMeasurementOfOperatingLeaseLiabilities
1700000
CY2022Q4 erna Lease Termination Fee Payable
LeaseTerminationFeePayable
100000
CY2022Q4 erna Lease Termination Fee Payable
LeaseTerminationFeePayable
100000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1400000
CY2022 erna Initial Measurement Of Operating Lease Liabilities
InitialMeasurementOfOperatingLeaseLiabilities
200000
CY2022 erna Initial Measurement Of Operating Lease Rou Assets
InitialMeasurementOfOperatingLeaseROUAssets
800000
CY2023Q1 erna Initial Measurement Of Operating Lease Liabilities
InitialMeasurementOfOperatingLeaseLiabilities
0
CY2023Q1 erna Initial Measurement Of Operating Lease Liabilities
InitialMeasurementOfOperatingLeaseLiabilities
0
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
68000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
186000
CY2022Q1 us-gaap Sublease Income
SubleaseIncome
21000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
5000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
3000
CY2023Q1 us-gaap Lease Cost
LeaseCost
52000
CY2022Q1 us-gaap Lease Cost
LeaseCost
168000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1030000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
41000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
989000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1182000
CY2023Q1 erna Principal Payments On Operating Lease Liabilities
PrincipalPaymentsOnOperatingLeaseLiabilities
173000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1009000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
841000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
168000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M18D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1023
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
203000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
272000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
274000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
267000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
163000
CY2023Q1 erna Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
82000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1261000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
252000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1009000
CY2023Q1 us-gaap Goodwill
Goodwill
2000000
CY2023Q1 erna Percentage Of Sublicense Fees Paid Before License Expiration Date
PercentageOfSublicenseFeesPaidBeforeLicenseExpirationDate
0.20
CY2023Q1 erna Percentage Of Sublience Fees Received During Renewal Term
PercentageOfSublienceFeesReceivedDuringRenewalTerm
0.30
CY2023Q1 erna Notice Period For First Termination Of Contract
NoticePeriodForFirstTerminationOfContract
P120D
CY2023Q1 erna Legal Fees And Settlements
LegalFeesAndSettlements
595000
CY2022Q4 erna Legal Fees And Settlements
LegalFeesAndSettlements
1138000
CY2023Q1 erna Accrued Clinical Current
AccruedClinicalCurrent
510000
CY2022Q4 erna Accrued Clinical Current
AccruedClinicalCurrent
570000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
389000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
333000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
205000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1065000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
313000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
520000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2012000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3626000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
689000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1183000
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4713
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5281000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
670000

Files In Submission

Name View Source Status
0001140361-23-024180-index-headers.html Edgar Link pending
0001140361-23-024180-index.html Edgar Link pending
0001140361-23-024180.txt Edgar Link pending
0001140361-23-024180-xbrl.zip Edgar Link pending
brhc20052635_10q.htm Edgar Link pending
brhc20052635_ex31-1.htm Edgar Link pending
brhc20052635_ex31-2.htm Edgar Link pending
brhc20052635_ex32-1.htm Edgar Link pending
brhc20052635_ex32-2.htm Edgar Link pending
erna-20230331.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image00007.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
erna-20230331_cal.xml Edgar Link unprocessable
erna-20230331_def.xml Edgar Link unprocessable
erna-20230331_pre.xml Edgar Link unprocessable
erna-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
brhc20052635_10q_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending